S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
The top-rated strong-buy stocks on Marketbeat’s radar
Why Microsoft Just Placed A Huge Bet On Nuclear (Ad)
Marketbeat’s AI-powered tools for investors
Are blue chip stocks a good investment?
The Only Practical Solution to the World’s Looming Energy Crisis (Ad)
As Dollar Tree Goes, So Goes the Consumer?
Power Play: GE's game-changing technology for EVs and grids
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Is Beyond an overlooked e-commerce winner?
Inflation in Europe falls to 2.4% as interest rates pack a punch. But the economy has stalled

Adaptive Biotechnologies Stock Price, News & Analysis (NASDAQ:ADPT)

$4.38
-0.24 (-5.19%)
(As of 11/30/2023 ET)
Compare
Today's Range
$4.31
$4.70
50-Day Range
$3.46
$5.64
52-Week Range
$2.61
$10.79
Volume
1.38 million shs
Average Volume
1.16 million shs
Market Capitalization
$634.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Adaptive Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
116.9% Upside
$9.50 Price Target
Short Interest
Bearish
7.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.79
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1,070 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.35) to ($1.10) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

534th out of 949 stocks

Biological Products, Except Diagnostic Industry

87th out of 163 stocks


ADPT stock logo

About Adaptive Biotechnologies Stock (NASDAQ:ADPT)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

ADPT Stock Price History

ADPT Stock News Headlines

ADPT Nov 2016 40.000 put
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Scotiabank Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
TD Cowen Keeps Their Buy Rating on Adaptive Biotechnologies (ADPT)
Why Microsoft Just Placed A Huge Bet On Nuclear
Even with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.
What's Going On With Adaptive Biotechnologies (ADPT) Stock?
Adaptive Announces Launch of Epic Integration for clonoSEQ®
Piper Sandler Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)
See More Headlines
Receive ADPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/02/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADPT
Employees
790
Year Founded
2009

Price Target and Rating

Average Stock Price Target
$9.50
High Stock Price Target
$15.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+116.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-200,190,000.00
Net Margins
-109.04%
Pretax Margin
-109.08%

Debt

Sales & Book Value

Annual Sales
$185.31 million
Book Value
$2.50 per share

Miscellaneous

Free Float
137,245,000
Market Cap
$634.09 million
Optionable
Not Optionable
Beta
1.28

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives















ADPT Stock Analysis - Frequently Asked Questions

Should I buy or sell Adaptive Biotechnologies stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADPT, but not buy additional shares or sell existing shares.
View ADPT analyst ratings
or view top-rated stocks.

What is Adaptive Biotechnologies' stock price target for 2024?

5 brokers have issued 1-year target prices for Adaptive Biotechnologies' shares. Their ADPT share price targets range from $6.00 to $15.00. On average, they predict the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 116.9% from the stock's current price.
View analysts price targets for ADPT
or view top-rated stocks among Wall Street analysts.

How have ADPT shares performed in 2023?

Adaptive Biotechnologies' stock was trading at $7.64 on January 1st, 2023. Since then, ADPT shares have decreased by 42.7% and is now trading at $4.38.
View the best growth stocks for 2023 here
.

When is Adaptive Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our ADPT earnings forecast
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.33) EPS for the quarter, hitting analysts' consensus estimates of ($0.33). The business earned $48.93 million during the quarter, compared to the consensus estimate of $44.87 million. Adaptive Biotechnologies had a negative trailing twelve-month return on equity of 47.63% and a negative net margin of 109.04%. The firm's quarterly revenue was up 12.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.37) EPS.

What ETFs hold Adaptive Biotechnologies' stock?

ETFs with the largest weight of Adaptive Biotechnologies (NASDAQ:ADPT) stock in their portfolio include ARK Genomic Revolution ETF (ARKG) and ETFMG Treatments Testing and Advancements ETF (GERM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).

What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?

51 employees have rated Adaptive Biotechnologies Chief Executive Officer Chad Robins on Glassdoor.com. Chad Robins has an approval rating of 92% among the company's employees. This puts Chad Robins in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (7.96%), Sumitomo Mitsui Trust Holdings Inc. (4.54%), Massachusetts Financial Services Co. MA (1.36%), Federated Hermes Inc. (0.96%), Principal Financial Group Inc. (0.86%) and Northern Trust Corp (0.72%). Insiders that own company stock include Chad M Cohen, Chad M Cohen, Chad M Robins, Chad M Robins, Charles Sang, David E Goel, Egon Durban, Eric Dobmeier, Euclidean Capital Llc, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Harlan S Robins, Julie Rubinstein, Jyoti Palaniappan, Kyle Piskel, Lance Baldo, Michael J Pellini, Michelle Renee Griffin, Nancy Louise Hill, Nitin Sood, R Mark Adams, Robert Hershberg, Sharon Benzeno, Stacy L Taylor and Tycho Peterson.
View institutional ownership trends
.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ADPT) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -